Buy xlo?

Advice: Considering the significant percentage change and positive news surrounding Xilio Therapeutics (XLO), it is advisable to exercise caution and conduct further research before making an investment decision.

Analysis:

1. Stock Performance: XLO has experienced a substantial percentage change of 69.01% on March 28, 2024, with a closing price of $1.08. This indicates a strong short-term performance.

2. Licensing Agreement: The recent surge in XLO's stock price is attributed to the exclusive license agreement with Gilead Sciences for XTX301, a tumor-activated IL-12 undergoing Phase 1 clinical trial. This partnership transfers development and commercialization responsibilities to Gilead, while Xilio retains clinical trial management.

3. Market Sentiment: XLO is mentioned alongside other healthcare stocks that experienced gains on the same day, with Avalo Therapeutics Inc (AVTX) showing a significant increase. However, XLO's gain is lower compared to AVTX.

Conclusion: The recent surge in XLO's stock price is primarily due to the promising licensing agreement with Gilead Sciences. However, given the high volatility and the relatively lower gain compared to other stocks mentioned in the news, it is crucial to conduct a comprehensive analysis of XLO's long-term prospects, competitive position, and Gilead's involvement in the development process. Investors should consider this information alongside their risk tolerance and investment horizon before making a decision to buy XLO shares.